drugset / Trial / NCT06421701

Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus

NCT06421701

NaSingle-groupOpen-labelTreatment

Summary

This study is a single-center, open-label, single-arm trial. The aim of this study is to investigate the safety and efficacy of anti-CD19 CAR-NK cells in patients with refractory/relapsed systemic lupus erythematosus.

Timeline

Start
2024-08-01
Primary completion
2025-08-01
Completion
2026-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject anti-CD19 CAR NK cells Cell therapy
Background Cyclophosphamide Other / unclassified
Background Fludarabine Small molecule